Aurobindo Pharma Reports 32.5% Profit Rise and Record Quarterly Revenue
Aurobindo Pharma reported a 32.5% year-on-year rise in net profit to approximately Rs 1,124 crore for the September quarter, driven by strong growth in the US and European markets. The company achieved its highest-ever quarterly revenue of Rs 10,263 crore, up nearly 24%, supported by new product launches and acquisitions. EBITDA margin improved to 21%, with formulations and API businesses both showing significant growth. The company declared an interim dividend of Rs 7 per share and emphasized sustainable growth and financial discipline.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 36/100.
Outlets measured: moneycontrol, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 4 Nov, 03:45 pm. Other outlets followed.